ACELRX PHARMACEUT. DL-01 (F:R5XA) — Stock Price
ACELRX PHARMACEUT. DL-01 (F:R5XA) is currently trading at €1.21 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €0.32 and €1.24. This page tracks ACELRX PHARMACEUT. DL-01's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ACELRX PHARMACEUT. DL-01 (R5XA) total market value.
ACELRX PHARMACEUT. DL-01 (R5XA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ACELRX PHARMACEUT. DL-01's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
ACELRX PHARMACEUT. DL-01 Income Statement — Revenue, Profit & Earnings by Year
ACELRX PHARMACEUT. DL-01's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €28.00K | €0.00 | €651.00K | €0.00 | €2.82 Million |
| Cost of Revenue | — | — | — | €2.59 Million | €3.75 Million |
| Gross Profit | — | — | — | €-820.00K | €-935.00K |
| Research & Development | €6.03 Million | €6.72 Million | €5.55 Million | €3.34 Million | €4.09 Million |
| SG&A | €7.48 Million | €8.53 Million | €11.99 Million | €17.01 Million | €30.93 Million |
| Total Operating Expenses | €13.51 Million | €15.25 Million | €17.54 Million | €20.35 Million | €38.78 Million |
| Operating Income | €-13.48 Million | €-15.25 Million | €-16.89 Million | €-20.35 Million | €-35.97 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €0.00 | €394.00K | €134.00K | €1.12 Million | €2.29 Million |
| Income Before Tax | €-14.36 Million | €-13.00 Million | €-10.29 Million | €59.14 Million | €-35.09 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-14.29 Million | €-13.00 Million | €-18.40 Million | €47.76 Million | €-35.10 Million |
ACELRX PHARMACEUT. DL-01 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ACELRX PHARMACEUT. DL-01's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €29.72 Million | €18.24 Million | €20.39 Million | €47.49 Million | €77.89 Million |
| Total Current Assets | €20.90 Million | €9.42 Million | €11.58 Million | €24.57 Million | €50.49 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €14.49 Million | €0.00 | €3.66 Million | €495.00K | €38.97 Million |
| Net Receivables | — | — | — | €309.00K | €160.00K |
| Inventory | — | — | — | €1.18 Million | €1.11 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €12.68 Million | €10.23 Million | €6.29 Million | €25.67 Million | €113.79 Million |
| Total Current Liabilities | €3.81 Million | €2.65 Million | €4.51 Million | €13.77 Million | €18.51 Million |
| Long-term Debt | — | — | — | — | €5.01 Million |
| Net Debt | — | — | — | — | €6.14 Million |
| Total Stockholder Equity | €17.04 Million | €8.00 Million | €14.11 Million | €21.81 Million | €-35.89 Million |
| Retained Earnings | €-471.52 Million | €-457.23 Million | €-444.23 Million | €-425.83 Million | €-473.58 Million |
ACELRX PHARMACEUT. DL-01 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ACELRX PHARMACEUT. DL-01 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-11.36 Million | €-12.68 Million | €-17.49 Million | €-28.33 Million | €-30.00 Million |
| Capital Expenditures | €0.00 | €0.00 | €100.00K | €364.00K | €1.83 Million |
| Free Cash Flow | €-11.36 Million | €-12.68 Million | €-17.59 Million | €-28.70 Million | €-31.83 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €22.74 Million | €12.04 Million | €3.47 Million | €-507.00K | €41.51 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €699.00K | €989.00K | €1.73 Million | €2.89 Million | €4.61 Million |
| Depreciation | — | €0.00 | €311.00K | €1.65 Million | €1.97 Million |
| Change in Cash | €-2.97 Million | €3.14 Million | €-14.55 Million | €7.61 Million | €-14.61 Million |
ACELRX PHARMACEUT. DL-01 Earnings History — EPS Actual vs. Analyst Estimates
Track ACELRX PHARMACEUT. DL-01's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 13, 2026 | — | -0.08 | — |
| Mar 04, 2026 | — | -0.07 | — |
| Nov 12, 2025 | — | -0.12 | — |
| Aug 12, 2025 | — | — | — |
| May 12, 2025 | — | — | — |
| Mar 04, 2025 | — | — | — |
| Nov 06, 2024 | — | — | — |